Drug Profile
Research programme: R-Ras signaling modulators - VBS Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator VBS Pharmaceuticals
- Class
- Mechanism of Action Ras protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Respiratory distress syndrome; Vascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-distress-syndrome in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in USA